KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

CRISPR Therapeutics AG (CRSP) Equity Income: 2016-2019

Historic Equity Income for CRISPR Therapeutics AG (CRSP) over the last 4 years, with Dec 2019 value amounting to -$5.5 million.

  • CRISPR Therapeutics AG's Equity Income fell 238.93% to -$3.4 million in Q3 2019 from the same period last year, while for Sep 2019 it was -$6.5 million, marking a year-over-year decrease of 74.87%. This contributed to the annual value of -$5.5 million for FY2019, which is 27.88% down from last year.
  • Latest data reveals that CRISPR Therapeutics AG reported Equity Income of -$5.5 million as of FY2019, which was down 27.88% from -$4.3 million recorded in FY2018.
  • CRISPR Therapeutics AG's Equity Income's 5-year high stood at -$1.8 million during FY2017, with a 5-year trough of -$36.5 million in FY2016.
  • Moreover, its 3-year median value for Equity Income was -$4.3 million (2018), whereas its average is -$3.8 million.
  • Per our database at Business Quant, CRISPR Therapeutics AG's Equity Income surged by 95.17% in 2017 and then tumbled by 142.48% in 2018.
  • CRISPR Therapeutics AG's Equity Income (Yearly) stood at -$36.5 million in 2016, then skyrocketed by 95.17% to -$1.8 million in 2017, then tumbled by 142.48% to -$4.3 million in 2018, then dropped by 27.88% to -$5.5 million in 2019.